After participating in a clinical trial, patients may wish to continue treatment with the trial medicine, yet the medicine may be years away from commercial availability.
TannerMAP partners with biopharmaceutical companies to maintain patient access to medicines after clinical trials, but before marketing approval.
Compassionate Use in Action
A global pharmaceutical company with a novel medicine for the treatment of migraine headaches had just completed a phase II clinical trial in the United States and had patients wanting to continue therapy.
WHY PARTNER WITH TANNERMAP ON A MANAGED ACCESS PROGRAM?
Expand access to more markets and earlier than planned by utilizing TannerMAP’s global GDP-compliant supply chain and regulatory expertise to import medicines into countries where marketing is not yet approved.
Reduce the administrative workload by authorizing TannerMAP to manage the requirements of validating patients and institutions that participate in a Managed Access Program.
Gain broader insights on product efficacy and demand to help inform future commercialization strategies and complement clinical trial findings by tapping into TannerMAP’s data collection and reporting services.
Build awareness with physicians, hospitals, pharmacists, regulators and patients by letting TannerMAP help develop and deliver a customized and compliant Managed Access Program.